1ny0

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (00:18, 21 November 2024) (edit) (undo)
 
(14 intermediate revisions not shown.)
Line 1: Line 1:
-
[[Image:1ny0.gif|left|200px]]
 
-
{{Structure
+
==Crystal Structure of the complex between M182T mutant of TEM-1 and a boronic acid inhibitor (NBF)==
-
|PDB= 1ny0 |SIZE=350|CAPTION= <scene name='initialview01'>1ny0</scene>, resolution 1.75&Aring;
+
<StructureSection load='1ny0' size='340' side='right'caption='[[1ny0]], [[Resolution|resolution]] 1.75&Aring;' scene=''>
-
|SITE=
+
== Structural highlights ==
-
|LIGAND= <scene name='pdbligand=K:POTASSIUM+ION'>K</scene>, <scene name='pdbligand=NBF:[(2-ETHOXY-1-NAPHTHOYL)AMINO]METHYLBORONIC+ACID'>NBF</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene>
+
<table><tr><td colspan='2'>[[1ny0]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Escherichia_coli Escherichia coli]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1NY0 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=1NY0 FirstGlance]. <br>
-
|ACTIVITY= <span class='plainlinks'>[http://en.wikipedia.org/wiki/Beta-lactamase Beta-lactamase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.5.2.6 3.5.2.6] </span>
+
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.75&#8491;</td></tr>
-
|GENE= bla ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=562 Escherichia coli])
+
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=K:POTASSIUM+ION'>K</scene>, <scene name='pdbligand=NBF:[(2-ETHOXY-1-NAPHTHOYL)AMINO]METHYLBORONIC+ACID'>NBF</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr>
-
|DOMAIN=
+
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=1ny0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1ny0 OCA], [https://pdbe.org/1ny0 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=1ny0 RCSB], [https://www.ebi.ac.uk/pdbsum/1ny0 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=1ny0 ProSAT]</span></td></tr>
-
|RELATEDENTRY=
+
</table>
-
|RESOURCES=<span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1ny0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1ny0 OCA], [http://www.ebi.ac.uk/pdbsum/1ny0 PDBsum], [http://www.rcsb.org/pdb/explore.do?structureId=1ny0 RCSB]</span>
+
== Function ==
-
}}
+
[https://www.uniprot.org/uniprot/BLAT_ECOLX BLAT_ECOLX] TEM-type are the most prevalent beta-lactamases in enterobacteria; they hydrolyze the beta-lactam bond in susceptible beta-lactam antibiotics, thus conferring resistance to penicillins and cephalosporins. TEM-3 and TEM-4 are capable of hydrolyzing cefotaxime and ceftazidime. TEM-5 is capable of hydrolyzing ceftazidime. TEM-6 is capable of hydrolyzing ceftazidime and aztreonam. TEM-8/CAZ-2, TEM-16/CAZ-7 and TEM-24/CAZ-6 are markedly active against ceftazidime. IRT-4 shows resistance to beta-lactamase inhibitors.
 +
== Evolutionary Conservation ==
 +
[[Image:Consurf_key_small.gif|200px|right]]
 +
Check<jmol>
 +
<jmolCheckbox>
 +
<scriptWhenChecked>; select protein; define ~consurf_to_do selected; consurf_initial_scene = true; script "/wiki/ConSurf/ny/1ny0_consurf.spt"</scriptWhenChecked>
 +
<scriptWhenUnchecked>script /wiki/extensions/Proteopedia/spt/initialview03.spt</scriptWhenUnchecked>
 +
<text>to colour the structure by Evolutionary Conservation</text>
 +
</jmolCheckbox>
 +
</jmol>, as determined by [http://consurfdb.tau.ac.il/ ConSurfDB]. You may read the [[Conservation%2C_Evolutionary|explanation]] of the method and the full data available from [http://bental.tau.ac.il/new_ConSurfDB/main_output.php?pdb_ID=1ny0 ConSurf].
 +
<div style="clear:both"></div>
 +
<div style="background-color:#fffaf0;">
 +
== Publication Abstract from PubMed ==
 +
Developing antimicrobials that are less likely to engender resistance has become an important design criterion as more and more drugs fall victim to resistance mutations. One hypothesis is that the more closely an inhibitor resembles a substrate, the more difficult it will be to develop resistant mutations that can at once disfavor the inhibitor and still recognize the substrate. To investigate this hypothesis, 10 transition-state analogues, of greater or lesser similarity to substrates, were tested for inhibition of TEM-1 beta-lactamase, the most widespread resistance enzyme to penicillin antibiotics. The inhibitors were also tested against four characteristic mutant enzymes: TEM-30, TEM-32, TEM-52, and TEM-64. The inhibitor most similar to the substrate, compound 10, was the most potent inhibitor of the WT enzyme, with a K(i) value of 64 nM. Conversely, compound 10 was the most susceptible to the TEM-30 (R244S) mutant, for which inhibition dropped by over 100-fold. The other inhibitors were relatively impervious to the TEM-30 mutant enzyme. To understand recognition and resistance to these transition-state analogues, the structures of four of these inhibitors in complex with TEM-1 were determined by X-ray crystallography. These structures suggest a structural basis for distinguishing inhibitors that mimic the acylation transition state and those that mimic the deacylation transition state; they also suggest how TEM-30 reduces the affinity of compound 10. In cell culture, this inhibitor reversed the resistance of bacteria to ampicillin, reducing minimum inhibitory concentrations of this penicillin by between 4- and 64-fold, depending on the strain of bacteria. Notwithstanding this activity, the resistance of TEM-30, which is already extant in the clinic, suggests that there can be resistance liabilities with substrate-based design.
-
'''Crystal Structure of the complex between M182T mutant of TEM-1 and a boronic acid inhibitor (NBF)'''
+
Recognition and resistance in TEM beta-lactamase.,Wang X, Minasov G, Blazquez J, Caselli E, Prati F, Shoichet BK Biochemistry. 2003 Jul 22;42(28):8434-44. PMID:12859188<ref>PMID:12859188</ref>
 +
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
 +
</div>
 +
<div class="pdbe-citations 1ny0" style="background-color:#fffaf0;"></div>
-
==Overview==
+
==See Also==
-
Developing antimicrobials that are less likely to engender resistance has become an important design criterion as more and more drugs fall victim to resistance mutations. One hypothesis is that the more closely an inhibitor resembles a substrate, the more difficult it will be to develop resistant mutations that can at once disfavor the inhibitor and still recognize the substrate. To investigate this hypothesis, 10 transition-state analogues, of greater or lesser similarity to substrates, were tested for inhibition of TEM-1 beta-lactamase, the most widespread resistance enzyme to penicillin antibiotics. The inhibitors were also tested against four characteristic mutant enzymes: TEM-30, TEM-32, TEM-52, and TEM-64. The inhibitor most similar to the substrate, compound 10, was the most potent inhibitor of the WT enzyme, with a K(i) value of 64 nM. Conversely, compound 10 was the most susceptible to the TEM-30 (R244S) mutant, for which inhibition dropped by over 100-fold. The other inhibitors were relatively impervious to the TEM-30 mutant enzyme. To understand recognition and resistance to these transition-state analogues, the structures of four of these inhibitors in complex with TEM-1 were determined by X-ray crystallography. These structures suggest a structural basis for distinguishing inhibitors that mimic the acylation transition state and those that mimic the deacylation transition state; they also suggest how TEM-30 reduces the affinity of compound 10. In cell culture, this inhibitor reversed the resistance of bacteria to ampicillin, reducing minimum inhibitory concentrations of this penicillin by between 4- and 64-fold, depending on the strain of bacteria. Notwithstanding this activity, the resistance of TEM-30, which is already extant in the clinic, suggests that there can be resistance liabilities with substrate-based design.
+
*[[Beta-lactamase 3D structures|Beta-lactamase 3D structures]]
-
 
+
== References ==
-
==About this Structure==
+
<references/>
-
1NY0 is a [[Single protein]] structure of sequence from [http://en.wikipedia.org/wiki/Escherichia_coli Escherichia coli]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1NY0 OCA].
+
__TOC__
-
 
+
</StructureSection>
-
==Reference==
+
-
Recognition and resistance in TEM beta-lactamase., Wang X, Minasov G, Blazquez J, Caselli E, Prati F, Shoichet BK, Biochemistry. 2003 Jul 22;42(28):8434-44. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/12859188 12859188]
+
-
[[Category: Beta-lactamase]]
+
[[Category: Escherichia coli]]
[[Category: Escherichia coli]]
-
[[Category: Single protein]]
+
[[Category: Large Structures]]
-
[[Category: Blazquez, J.]]
+
[[Category: Blazquez J]]
-
[[Category: Caselli, E.]]
+
[[Category: Caselli E]]
-
[[Category: Minasov, G.]]
+
[[Category: Minasov G]]
-
[[Category: Prati, F.]]
+
[[Category: Prati F]]
-
[[Category: Shoichet, B K.]]
+
[[Category: Shoichet BK]]
-
[[Category: Wang, X.]]
+
[[Category: Wang X]]
-
[[Category: acylation transition-state analog]]
+
-
[[Category: antibiotic resistance]]
+
-
[[Category: beta-lactamase]]
+
-
[[Category: crystal structure]]
+
-
 
+
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun Mar 30 22:37:03 2008''
+

Current revision

Crystal Structure of the complex between M182T mutant of TEM-1 and a boronic acid inhibitor (NBF)

PDB ID 1ny0

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools